Clinical trials: HBV
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Chronic HBV Infection
Methylene Blue Treatment of Chronic Hepatitis B Virus Infection
HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease.
- Trial name
- MB_HBV (NCT06887036)
- Testing
- Methylene Blue
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Fondazione Epatocentro Ticino
Hepatitis B
Healthy Planet Hepatitis B
This quality improvement project utilizes Epic Health Planet to increase screening for chronic hepatitis B through the creation of registries and ordering of hepatitis B laboratory panels.
- Trial name
- NCT04503993
- Testing
- Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody
- Where
- United States
- Volunteers
- 5,004 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Chronic Hepatitis B
Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
The purpose is to evaluate efficacy and safety of therapeutic HBV vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal dosing schedule.
- Trial name
- NCT02862106
- Testing
- εPA-44
- Where
- 9 sites in China
- Volunteers
- 209 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Hepatitis B
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
- Trial name
- B-Focus (NCT06497504)
- Testing
- Bepirovirsen
- Where
- 51 sites in United States, Argentina and 8 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Chronic Hepatitis B
Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background
The purpose of this study is to investigate whether the combination of abatacept along with entecavir (the study drugs) is safe and effective in treating symptoms related to rheumatoid arthritis (RA).
- Trial name
- RA (NCT02053727)
- Testing
- Abatacept
- Where
- United States
- Sponsor
- University of California, Los Angeles
HBeAg Positive Chronic Hepatitis B Infection
Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection
During hepatitis B virus(HBV) infection host immune plays important role.Recently there are many different antiviral therapy methods.Different antiviral therapy methods showed different effector.In order to investigate whether…
- Trial name
- NCT01480492
- Testing
- Telbivudine
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Cz Li
Innate Immune Response
A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study
Neonatal morbidity and mortality from infectious diseases is of global concern. Childhood disease-specific immunisation is irrefutably linked to the decline in deaths from these targeted infections over the last century.
- Trial name
- ELVIS (NCT02444611)
- Testing
- BCG Vaccine, Hepatitis B Vaccine
- Where
- Australia
- Volunteers
- 185 people
- Sponsor
- Murdoch Childrens Research Institute
Chronic Hepatitis B
Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients
A multi-center and open study to compare the safety and effectiveness of switching treatment from lamivudine to clevudine for 24 weeks.
- Trial name
- NCT00558493
- Testing
- Clevudine
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis B
Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder
The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 15-16 years who were vaccinated with Engerix™-B Kinder in infancy.
- Trial name
- NCT01847430
- Testing
- Engerix™-B Kinder
- Where
- 10 sites in Germany
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hand, Foot and Mouth Disease
Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine
The main purpose of this study is to evaluate the immunogenicity and safety of inactivated enterovirus type 71 vaccine combined with recombinant hepatitis B vaccine or Group a meningococcal polysaccharide vaccine.
- Trial name
- NCT06209398
- Testing
- Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell ), Recombinant Hepatitis B Vaccine, Group A meningococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pain, Analgesia
Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B
Acute procedural pain in neonates may be alleviated by non-pharmacological procedures. This study objective is to test the efficacy regarding pain attenuation of 3 interventions (skin-to-skin contact versus glucose 25% versus…
- Trial name
- NCT00713986
- Testing
- Water 2mL PO 2 minutes prior to intra-muscular injection, skin-to-skin contact, Glucose 25% 2 mL PO 2 minutes prior to injection
- Volunteers
- 640 people
- Sponsor
- Federal University of São Paulo
Hepatitis B
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
Comparison of adjuvanted hepatitis B vaccine to double dose of Engerix™-B in pre- /haemodialysis patients aged ≥15 years.
- Trial name
- NCT00383383
- Testing
- Hepatitis B adjuvanted vaccine, Engerix-B
- Where
- 3 sites in Czechia, Malaysia and 1 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
HBeAg-Positive Chronic Hepatitis B
Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B
This is a multicenter, double blind, active-controlled, randomized, parallel group study to demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for patients with HBeAg Chronic Hepatitis B.
- Trial name
- NCT01913431
- Testing
- Baracle Tab.®, Baraclude Tab.®
- Where
- South Korea
- Volunteers
- 118 people
- Sponsor
- Dong-A ST Co., Ltd.
Unresectable Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including…
- Trial name
- ISMIO001 (NCT07204327)
- Testing
- Atezo+Bev plus Locoregional Therapy
- Where
- China
- Volunteers
- 1,136 people
- Sponsor
- Zhongda Hospital
Chronic Hepatitis B
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
- Trial name
- NCT00037622
- Testing
- ACH-126, 443 (beta-L-Fd4C)
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HBV, HBV/HDV
Rapid T-cell Analysis Test in Patients With Chronic HBV and HBV/HDV Disease
Prospective, non-pharmacological, single-center, non-profit observational study. The study design allows longitudinal evaluation of the immune response during the natural history of the infection and/or treatment, correlating the…
- Trial name
- BDTc (NCT06372990)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Occult Hepatitis B Infection in Cancer Patients
Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.
The goal of this observational study is to evalue the cumulative proportion of patients with OBI who do not develop HBsAg seroreversion and/or an increase of serum HBV DNA by at least 1 log above the lower limit of detection of…
- Trial name
- NCT06347588
- Testing
- Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Diphtheria, Tetanus
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
This is a randomized cross-sectional study of the Swedish population. Blood samples will be collected from a subpopulation in order to estimate the age specific sero-prevalence of the Swedish population for diseases included in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- Sero 2007 (NCT00932269)
- Where
- Sweden
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Hepatitis B, Hepatitis C
Epidemiology of Hepatitis B, C and Delta in Reunion Island
Viral hepatitis B, C and Δ represent a global public health problem for which France was very early mobilized. Despite this, in its foreword, the Dhumeaux report on "Management of people infected with hepatitis B or hepatitis C…
- Conditions
- Hepatitis B, Hepatitis C, Hepatitis D
- Trial name
- HEPEPID (NCT03362866)
- Volunteers
- 2,000 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion